Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

By Lars Zender, M. Spector, W. Xue, P. Flemming, C. Cordon-Cardo, J. Silke, S. Fan, J. Luk, M. Wigler, Gregory J. Hannon and 4 more. Cell, 2006

1,142 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/758dd87ff6e8626b2b2446f9e05be45c58c86a3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. K. Guan
2. Bin Zhao
3. G. Halder
4. Duojia Pan
5. Fa-Xing Yu
6. S. Piccolo
7. M. Cordenonsi
8. Xaralabos Varelas

In Molecular Biology

1. K. Guan
2. Duojia Pan
3. Bin Zhao
4. G. Halder
5. Fa-Xing Yu
6. S. Piccolo
7. Xaralabos Varelas
8. David M. Sabatini

Citations in the corpus

• YAP/TAZ at the roots of cancer (2016, background): “YAP or TAZ knockdown strongly reduces subcutaneous tumor growth of human and mouse HCC cell lines (Xiao et al., 2015; Xiao et al., 2013; Zender et al., 2006).”
• The landscape of somatic copy-number alteration across human cancers (2010, neutral): “PPAP2C (10) MACROD2 (2) PPM1F (3) Amplifications Deletions Chr”
• A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). (2010, background): “72 GENES & DEVELOPMENT 24:72–85 2010 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/10; www.genesdev.org implicated in cell contact inhibition and tissue growth control (Zhao et al. 2007; Zeng and Hong 2008).”
• Hippo signaling in organ size control. (2007, background): “Using a mouse model of liver cancer initiated from progenitor cells harboring p53 loss and c-myc overexpression, Zender et al. (2006) found a recurrent amplification at mouse chromosome 9qA1 that accelerates the rapid growth of tumors.”
• IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer (2010, background): “Moreover, recurrent amplification of Birc2 and Birc3 also frequently occurs in mouse models of MYC -driven liver cancer and spontaneous osteosarcoma”
• Identification of RPS14 as a 5q- syndrome gene by RNA interference screen (2008, neutral): “The increased 30S/18SE ratio in RPS14-deficient cells was not simply a consequence of cell death: the ribosomal processing defect occurred before the onset of significant apoptosis, and pharmacologically induced apoptosis failed to generate the characteristic 30S/18S defect (Supplementary Figs 8 and”
• Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling (2012, background): “Moreover, abnormal activation of YAP and TAZ has been associated with human cancers (Overholtzer et al., 2006; Steinhardt et al., 2008; Zender et al., 2006; Zhao et al., 2007), suggesting an important role for the Hippo pathway in tumorigenesis.”
• Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. (2012, background): “…cells Accumulating evidence supports an oncogenic role of YAP and a tumor suppressor function of the Hippo pathway (Overholtzer et al. 2006; Zender et al. 2006; Zhao et al. 2007; Steinhardt et al. 2008; Xu et al. 2009; Zhou et al. 2009; Lee et al. 2010; Lu et al. 2010; Pan 2010; Song et…”
• Integrative genomic approaches identify IKBKE as a breast cancer oncogene. (2007, background): “Indeed, recent applications of these technologies led to the identification of MITF, c-IAP1, and YAP as human oncogenes (Garraway et al., 2005; Zender et al., 2006).”
• Is NF-κB a good target for cancer therapy? Hopes and pitfalls (2009, background): “, and genetic amplification of cIAP1 was suggested to promote tumorigenesis and sustain tumour growth in a mouse model of liver cance”